Related Experiment Videos
[Three interesting pediatric cases with penicillin-resistant Streptococcus pneumoniae infection]
K Terada1, I Nishigaki, R Murakami
1Department of Pediatrics, Kawasaki Medical School.
Summary
Penicillin-resistant Streptococcus pneumoniae is a growing global threat, with rates up to 50% in Japanese pediatric cases. This study highlights three pediatric cases of resistant pneumococcal infections, offering clinical insights for managing this challenge.
Area of Science:
- Pediatric Infectious Diseases
- Microbiology
- Clinical Medicine
Background:
- Penicillin-resistant Streptococcus pneumoniae (PRSP) emerged in 1967 and has shown a significant global increase.
- Pediatric infections caused by PRSP are a growing concern, reaching up to 50% in some regions like Japan.
- Effective clinical strategies are needed to combat the rising prevalence of resistant pneumococcal strains.
Observation:
- Three distinct pediatric cases of penicillin G-resistant Streptococcus pneumoniae infections were documented.
- Case 1: Acute mastoiditis, a presentation less common than masked mastoiditis in recent clinical experience.
- Case 2: Meningitis with septicemia, initially presenting with normal cerebrospinal fluid findings.
- Case 3: Recurrent bronchitis in a pediatric patient with cerebral palsy.
Findings:
- Minimum inhibitory concentrations (MICs) for the isolated strains varied, with 0.25 µg/ml in the second case and 2.0 µg/ml in the first and third cases.
- The diverse clinical presentations underscore the varied manifestations of resistant pneumococcal infections in children.
- These cases provide valuable data on the susceptibility patterns of contemporary PRSP strains.
Implications:
- The findings offer crucial insights for clinicians managing pediatric patients with suspected or confirmed resistant pneumococcal infections.
- Understanding the clinical spectrum and susceptibility patterns of PRSP is vital for timely and appropriate treatment decisions.
- This case series contributes to the ongoing efforts to address the global challenge of antimicrobial resistance in Streptococcus pneumoniae.